The minutes of the vaccine expert group meeting is out and it shows that the approval of Bharat Biotech's Covaxin was based on non-human primate challenge study.
Recommended Articles
View All
Vodafone-Idea Saga — Three parents but none to love
Feb 6, 2023 IST6 Min(s) Read
World Cancer Day 2023: Early detection is crucial for reducing the global burden
Feb 4, 2023 IST5 Min(s) Read
World Cancer Day 2023: A way forward to better management of cancer this year!
Feb 4, 2023 IST6 Min(s) Read
Pakistan economy at alarming level as foreign reserves drop to $3.1 billion from $16.6 billion in a year
Feb 3, 2023 IST3 Min(s) Read
The minutes of the Subject Expert Committee (SEC) revealed now that the approval under clinical trial mode that has been given based on non-human primate challenge study, which was submitted after multiple times when the Bharat Biotech application was rejected and sent back by the SEC.
On December, 13th SEC has told Bharat Biotech that they need to submit updated immunogenicity, safety, and efficacy dated for further consideration.
CNBC-TV18’s Archana Shukla gets more details.
To know more, watch this video.